GlassScriptPhysician profile
Dharmesh A Mehta
NPI 1629381363
$7,418.67
in general payments reported to CMS, 2019-2025
37 companies · $4,033 in 2025
The $4,033 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $877 · 2020: $62.86 · 2021: $697 · 2022: $443 · 2023: $469 · 2024: $837 · 2025: $4,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,638 · Consulting Fee: $2,610 · Travel and Lodging: $91.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,638.35 |
| Consulting Fee | $2,609.50 |
| Travel and Lodging | $91.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $3,400.91 | 2021-2025 | |
| Vertiflex, INC. | $706.13 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $443.60 | 2021-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $414.25 | 2021-2025 | Farxiga, Airsupra, Lokelma |
| Lilly USA, LLC | $340.62 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $210.75 | 2019-2025 | |
| Pfizer INC. | $201.17 | 2021-2025 | |
| Novo Nordisk INC | $199.47 | 2020-2024 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $125.20 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Horizon Therapeutics Plc | $109.43 | 2023 | Krystexxa |
| Corcept Therapeutics | $98.76 | 2025 | Korlym |
| Inspire Medical Systems, INC. | $94.34 | 2025 | Inspire |
| Lundbeck LLC | $90.36 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $89.47 | 2021-2022 | |
| Abbott Laboratories | $89.10 | 2021-2025 | Freestyle Libre 3 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dharmesh Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.